Evidence map›Paper›PMID 27155666›Full record

ArticleJournal of cancer research and clinical oncology2016

Exploring an herbal "wonder cure" for cancer: a multidisciplinary approach.

Eran Ben-Arye, Jamal Mahajna, Radi Aly, Mohammed Saleem Ali-Shtayeh, Yedidia Bentur, Efraim Lev, Gary Deng, Noah Samuels

Abstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Assessment of the anti-cancer potential ofSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  3. The Canadian journal of hospital pharmacy · 2024
    Article
  4. Bio-Guided Assay ofMolecules (Basel, Switzerland) · 2023
    Article
  5. Article
  6. Review
  7. A Review of theMolecules (Basel, Switzerland) · 2020
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eran Ben-AryeIntegrative Oncology Program, Haifa and Western Galilee Oncology Service, Clalit Health Services, Haifa, Israel. eranben@netvision.net.il.
Jamal MahajnaCancer Drug Discovery Program, Galilee Technology Center, Kiryat Shmona, Israel.
Radi AlyDepartment of Plant Pathology and Weed Research, ARO, Newe-Yaar Research Center, Ramat Yishay, Israel.
Mohammed Saleem Ali-ShtayehBiodiversity and Biotechnology Research Unit, Biodiversity and Environmental Research Center, BERC, Til, Nablus, Palestine.
Yedidia BenturIsrael Poison Information Center, Section of Clinical Pharmacology and Toxicology, Rambam Health Care Campus, The Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Efraim LevDepartment of Eretz Israel Studies, University of Haifa, Haifa, Israel.
Gary DengIntegrative Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Noah SamuelsIntegrative Oncology Program, Haifa and Western Galilee Oncology Service, Clalit Health Services, Haifa, Israel.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

CONTEXT AND

objectivesThe unmonitored use of herbal medicinal remedies by patients with cancer presents a significant challenge to oncology healthcare professionals. We describe an increasingly popular herbal "wonder drug," Ephedra foeminea (Alanda in Arabic), whose use has spread from the Palestinian patient population throughout the Middle East. We conducted a multicentered and multidisciplinary collaborative research effort in order to understand the potential benefits and harms of this popular herbal remedy.

methodsWe conducted an in-depth search of the medical literature, both traditional and modern, for any mention of the clinical use of Alanda for the treatment of cancer. We then tested the remedy, first for toxic ephedra alkaloid components and then for anticancer effects, as well as effects on the cytotoxic activity of chemotherapy agents (cisplatin and carboplatin) on breast cancer cell cultures.

resultsWe found no mention in the literature, both conventional and traditional, on the use of Alanda for the treatment of cancer. Laboratory testing did not find any toxic components (i.e., ephedra alkaloids) in the preparation. However, in vitro exposure to Alanda led to a reduced cytotoxic effect of chemotherapy on breast cancer cell cultures.

conclusionsThe use of an integrative ethnobotanical, laboratory and clinical research-based approach can be extremely helpful when providing nonjudgmental and evidence-based guidance to patients with cancer, especially on the use of traditional herbal medicine. The effectiveness and safety of these products need to be examined by integrative physicians who are dually trained in both complementary medicine and supportive cancer care.

Indexed as

EphedraHerbal MedicineAntineoplastic AgentsHumansNeoplasmsAntineoplastic AgentsComplementary medicineDrug–herb interactionsEphedra foemineaHerbal medicineIntegrative medicineQuality-of-life (QOL)

Identifiers

PMID27155666
PMCPMC5513733

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.